首页 > 最新文献

Advances in Therapy最新文献

英文 中文
Transitioning Between Treprostinil Formulations: Evidence and Strategies. 曲前列地尼制剂之间的过渡:证据和策略。
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-10 DOI: 10.1007/s12325-025-03401-6
Megan Clarke, Ali Ataya, Alison M Turkin, Raj Parikh, Kyle Davis, Chad E Miller, Alexander Kantorovich, Thomas Winkler, Steven J Cassady

Treprostinil is a prostacyclin analog available in four formulations: parenteral, oral, inhalation solution, and inhalation powder. All formulations of treprostinil are indicated for the treatment of pulmonary arterial hypertension; the inhaled formulations are also approved for pulmonary hypertension associated with interstitial lung disease. Transitions between formulations are frequent in clinical practice but lack standardized guidance. This review summarizes published evidence regarding safety, efficacy, and techniques of transitioning between treprostinil formulations. The evidence includes over 100 patients across various settings, with crossover transition strategies most frequently employed. Approximately 80% of cases reviewed were deemed successful; however, it should be noted there was no standardized definition for success across publications. Unsuccessful transitions were often linked to disease progression or intolerance to therapy. These findings underscore the importance of individualized transition strategies, informed by clinical status, patient preferences, and formulation-specific pharmacokinetics. By consolidating the current evidence, this review aims to support clinicians in optimizing transitions and maintaining continuity of treprostinil therapy.Graphical abstract available for this article.

曲前列替尼是一种前列环素类似物,有四种剂型:静脉注射、口服、吸入溶液和吸入粉剂。所有曲前列地尼制剂均适用于肺动脉高压的治疗;吸入制剂也被批准用于与间质性肺疾病相关的肺动脉高压。在临床实践中,配方之间的转换经常发生,但缺乏标准化的指导。本综述总结了已发表的关于曲前列氨酯制剂的安全性、有效性和过渡技术的证据。证据包括来自不同环境的100多名患者,其中最常用的是交叉过渡策略。大约80%的审查案例被认为是成功的;但是,应该指出的是,对于出版物的成功并没有标准化的定义。不成功的转变通常与疾病进展或治疗不耐受有关。这些发现强调了个性化过渡策略的重要性,根据临床状况、患者偏好和配方特定的药代动力学进行调整。通过巩固现有的证据,本综述旨在支持临床医生优化过渡和维持曲前列地尼治疗的连续性。本文提供图形摘要。
{"title":"Transitioning Between Treprostinil Formulations: Evidence and Strategies.","authors":"Megan Clarke, Ali Ataya, Alison M Turkin, Raj Parikh, Kyle Davis, Chad E Miller, Alexander Kantorovich, Thomas Winkler, Steven J Cassady","doi":"10.1007/s12325-025-03401-6","DOIUrl":"10.1007/s12325-025-03401-6","url":null,"abstract":"<p><p>Treprostinil is a prostacyclin analog available in four formulations: parenteral, oral, inhalation solution, and inhalation powder. All formulations of treprostinil are indicated for the treatment of pulmonary arterial hypertension; the inhaled formulations are also approved for pulmonary hypertension associated with interstitial lung disease. Transitions between formulations are frequent in clinical practice but lack standardized guidance. This review summarizes published evidence regarding safety, efficacy, and techniques of transitioning between treprostinil formulations. The evidence includes over 100 patients across various settings, with crossover transition strategies most frequently employed. Approximately 80% of cases reviewed were deemed successful; however, it should be noted there was no standardized definition for success across publications. Unsuccessful transitions were often linked to disease progression or intolerance to therapy. These findings underscore the importance of individualized transition strategies, informed by clinical status, patient preferences, and formulation-specific pharmacokinetics. By consolidating the current evidence, this review aims to support clinicians in optimizing transitions and maintaining continuity of treprostinil therapy.Graphical abstract available for this article.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity. 肥胖人群饮食行为与食欲问卷(EBAQ)的编制与内容评价
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-07 DOI: 10.1007/s12325-025-03386-2
Chisom Kanu, Claudine Clucas, Anne Skalicky, Ashley Samuelson, Iris Goetz, Lisa M Neff, Kristina S Boye, Hayley Karn

Introduction: Obesity management medications can reduce body weight and have an impact on patients' appetite and eating behaviors. Existing patient-reported outcome (PRO) measures do not fully capture appetite and eating behavior concepts relevant to individuals living with obesity, including those receiving treatment. Here we describe the development and content evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ), a new PRO measure to enable a comprehensive assessment of appetite and eating behaviors which are important to individuals living with obesity.

Methods: The EBAQ was developed on the basis of findings from a targeted literature review, findings from exit interviews with participants (N = 40) in a phase 2 trial for retatrutide (NCT04881760), and interviews with clinicians specializing in obesity medicine (N = 3). Cognitive interviews were conducted with USA-based adults with obesity or with overweight and ≥ 1 obesity-related complications (hypertension, dyslipidemia, cardiovascular disease) (N = 24) to evaluate the content of the EBAQ.

Results: All 24 cognitive interview participants reported a positive overall impression of the EBAQ and that they understood the instructions and recall period. Most participants (n = 23, 96%) found the response options to be clear and appropriate. Items in the EBAQ were considered clear and relevant by the participants. The 21-item EBAQ is a new PRO measure with three domains to evaluate eight appetite and eating behavior concepts relevant to obesity and which may change with obesity treatment.

Conclusion: The EBAQ may be used in clinical trials, clinical practice, or observational research to evaluate the impact of obesity and the effect of obesity treatment on appetite and eating behaviors.

简介:肥胖管理药物可以降低体重,对患者的食欲和饮食行为产生影响。现有的患者报告结果(PRO)测量并不能完全捕捉到与肥胖个体相关的食欲和饮食行为概念,包括接受治疗的个体。本文介绍了饮食行为和食欲问卷(EBAQ)的开发和内容评估,EBAQ是一种新的PRO测量方法,可以全面评估对肥胖个体至关重要的食欲和饮食行为。方法:EBAQ是基于一项有针对性的文献综述,对利特鲁肽(NCT04881760) 2期试验参与者(N = 40)的退出访谈,以及对肥胖医学专业临床医生(N = 3)的访谈。对美国肥胖或超重且伴有≥1种肥胖相关并发症(高血压、血脂异常、心血管疾病)的成年人(N = 24)进行认知访谈,以评估EBAQ的含量。结果:所有24名认知访谈参与者对EBAQ的总体印象都是积极的,他们理解了指令和回忆时间。大多数参与者(n = 23,96%)认为回答选项是明确和适当的。与会者认为EBAQ中的项目明确和相关。21项EBAQ是一种新的PRO测量方法,包含三个域,用于评估与肥胖相关的8种食欲和饮食行为概念,这些概念可能会随着肥胖治疗而改变。结论:EBAQ可用于临床试验、临床实践或观察性研究,以评估肥胖的影响以及肥胖治疗对食欲和饮食行为的影响。
{"title":"Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.","authors":"Chisom Kanu, Claudine Clucas, Anne Skalicky, Ashley Samuelson, Iris Goetz, Lisa M Neff, Kristina S Boye, Hayley Karn","doi":"10.1007/s12325-025-03386-2","DOIUrl":"https://doi.org/10.1007/s12325-025-03386-2","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity management medications can reduce body weight and have an impact on patients' appetite and eating behaviors. Existing patient-reported outcome (PRO) measures do not fully capture appetite and eating behavior concepts relevant to individuals living with obesity, including those receiving treatment. Here we describe the development and content evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ), a new PRO measure to enable a comprehensive assessment of appetite and eating behaviors which are important to individuals living with obesity.</p><p><strong>Methods: </strong>The EBAQ was developed on the basis of findings from a targeted literature review, findings from exit interviews with participants (N = 40) in a phase 2 trial for retatrutide (NCT04881760), and interviews with clinicians specializing in obesity medicine (N = 3). Cognitive interviews were conducted with USA-based adults with obesity or with overweight and ≥ 1 obesity-related complications (hypertension, dyslipidemia, cardiovascular disease) (N = 24) to evaluate the content of the EBAQ.</p><p><strong>Results: </strong>All 24 cognitive interview participants reported a positive overall impression of the EBAQ and that they understood the instructions and recall period. Most participants (n = 23, 96%) found the response options to be clear and appropriate. Items in the EBAQ were considered clear and relevant by the participants. The 21-item EBAQ is a new PRO measure with three domains to evaluate eight appetite and eating behavior concepts relevant to obesity and which may change with obesity treatment.</p><p><strong>Conclusion: </strong>The EBAQ may be used in clinical trials, clinical practice, or observational research to evaluate the impact of obesity and the effect of obesity treatment on appetite and eating behaviors.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Adherence in Cardiovascular Diseases: Insights from the Patient and Physician-A Narrative Review. 心血管疾病的治疗依从性:来自患者和医生的见解-叙述回顾。
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-06 DOI: 10.1007/s12325-025-03413-2
Maria George, Inese Maurina, Aletta E Schutte

Therapeutic adherence is defined as the extent to which patients' medication-taking behaviour corresponds with agreed recommendations from a clinician. Adherence to cardiovascular therapies significantly improves outcomes and improves patient quality of life. However, adherence is often suboptimal in patients with cardiovascular disease. This narrative review aims to describe key barriers to adherence and identify practical actions that can be undertaken by all stakeholders to improve treatment adherence. Key barriers fall into categories related to the patient, medication, healthcare system, disease and society. These include, but are not limited to, logistical challenges faced by patients incorporating medication into their daily lives, fragmented care, the patient-physician relationship, the complexity of the regimen and medication costs. While macro-initiatives to remove health system and societal barriers are encouraged, there are many practical ways in which patients can also be supported to adhere to medication. These include improving communication techniques to build a trusting physician-patient relationship, engaging other healthcare professionals (e.g. nurses and pharmacists), referral to patient advocacy groups for reliable information and peer support, simplifying treatment regimens where safe and appropriate, the use of digital tools or devices (e.g. pill boxes and symptom trackers) that help patients to take their medication in the right dose and at the right time and consideration of the patient's budgetary constraints when prescribing. Prescribing formulations for once-daily administration and single-pill combinations can also help to simplify treatment regimens. No single solution will fit all patients, and initiatives to enhance adherence must also be tailored wherever possible to the individual patient's abilities, circumstances, values and beliefs.

治疗依从性被定义为患者服药行为与临床医生同意的建议相一致的程度。坚持心血管治疗可显著改善预后并提高患者的生活质量。然而,心血管疾病患者的依从性往往不是最佳的。这篇叙述性综述旨在描述坚持治疗的主要障碍,并确定所有利益攸关方可以采取的实际行动,以提高治疗的坚持性。主要障碍分为与患者、药物、医疗保健系统、疾病和社会相关的类别。这些挑战包括但不限于患者将药物纳入日常生活所面临的后勤挑战、分散的护理、医患关系、治疗方案的复杂性和药物费用。虽然鼓励消除卫生系统和社会障碍的宏观举措,但也有许多实际方法可以支持患者坚持服药。这些措施包括改进沟通技术以建立相互信任的医患关系,使其他保健专业人员(例如护士和药剂师)参与进来,转介给患者倡导团体以获得可靠信息和同伴支持,在安全和适当的情况下简化治疗方案,使用数字工具或设备(如药盒和症状追踪器),帮助患者在正确的时间以正确的剂量服药,并在开处方时考虑到患者的预算限制。每天服用一次的处方制剂和单丸组合也有助于简化治疗方案。没有任何一种解决方案能够适用于所有患者,而且还必须尽可能根据患者个人的能力、情况、价值观和信仰量身定制提高依从性的举措。
{"title":"Therapeutic Adherence in Cardiovascular Diseases: Insights from the Patient and Physician-A Narrative Review.","authors":"Maria George, Inese Maurina, Aletta E Schutte","doi":"10.1007/s12325-025-03413-2","DOIUrl":"https://doi.org/10.1007/s12325-025-03413-2","url":null,"abstract":"<p><p>Therapeutic adherence is defined as the extent to which patients' medication-taking behaviour corresponds with agreed recommendations from a clinician. Adherence to cardiovascular therapies significantly improves outcomes and improves patient quality of life. However, adherence is often suboptimal in patients with cardiovascular disease. This narrative review aims to describe key barriers to adherence and identify practical actions that can be undertaken by all stakeholders to improve treatment adherence. Key barriers fall into categories related to the patient, medication, healthcare system, disease and society. These include, but are not limited to, logistical challenges faced by patients incorporating medication into their daily lives, fragmented care, the patient-physician relationship, the complexity of the regimen and medication costs. While macro-initiatives to remove health system and societal barriers are encouraged, there are many practical ways in which patients can also be supported to adhere to medication. These include improving communication techniques to build a trusting physician-patient relationship, engaging other healthcare professionals (e.g. nurses and pharmacists), referral to patient advocacy groups for reliable information and peer support, simplifying treatment regimens where safe and appropriate, the use of digital tools or devices (e.g. pill boxes and symptom trackers) that help patients to take their medication in the right dose and at the right time and consideration of the patient's budgetary constraints when prescribing. Prescribing formulations for once-daily administration and single-pill combinations can also help to simplify treatment regimens. No single solution will fit all patients, and initiatives to enhance adherence must also be tailored wherever possible to the individual patient's abilities, circumstances, values and beliefs.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration 美国退伍军人健康管理局前列腺癌患者瑞路高利治疗模式和前列腺特异性抗原反应的种族差异回顾性分析
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-01 DOI: 10.1007/s12325-025-03390-6
Stephen J. Freedland, Krishnan Ramaswamy, Abhishek Kavati, Wei Gao, Juan F. Razo, Michele Cole, Benjamin Li, Hongbo Yang, Tracy Guo, Grace Chen, Rana R. McKay

Introduction

Relugolix is the only oral androgen deprivation therapy (ADT) approved for advanced prostate cancer (PC). Real-world evidence on treatment patterns and prostate-specific antigen (PSA) responses of relugolix, especially as a function of race, remain limited. This study assessed these outcomes and compared differences between Black and White patients.

Methods

Veterans Health Administration data were analyzed to identify male adults with PC who initiated relugolix between December 2020 and December 2023. Adherence to relugolix was assessed for up to 1 year after treatment initiation and was compared between races using generalized linear models. Discontinuation of relugolix, switching to another ADT, and initiating an add-on PC treatment were assessed using Kaplan–Meier analyses and compared between races using Cox regressions. PSA responses during relugolix treatment, including ≥ 50% and ≥ 90% decline from baseline and achieving < 0.2 ng/mL, were assessed among ADT-naïve patients.

Results

A total of 507 patients were identified (141 Black and 313 White patients). During the first 12 months of treatment, both races had > 90% adherence to relugolix with no significant differences between them. During follow-up (median 10.7 and 12.6 months for Black and White patients, respectively), 27.0% Black and 21.1% White patients discontinued relugolix; 9.2% Black and 3.8% White patients switched to another ADT; and 11.3% Black and 10.5% White patients initiated an add-on PC treatment. Among ADT-naïve patients, 87.2% Black and 87.2% White patients achieved PSA decline ≥ 50% from baseline; 69.2% and 64.1% achieved ≥ 90% decline; 51.3% and 47.4% achieved PSA < 0.2 ng/mL.

Conclusion

Adherence to relugolix was very high during the first year of treatment. These data support that in the real world, patients can adhere to relugolix with PSA responses on par with clinical trials regardless of race. Black patients were more likely to discontinue or switch to another ADT than White patients, but the reasons for this require further study.

Trial registration

ClinicalTrials.gov identifier, NCT06462014.

Relugolix是唯一被批准用于晚期前列腺癌(PC)的口服雄激素剥夺疗法(ADT)。关于relugolix的治疗模式和前列腺特异性抗原(PSA)反应的实际证据,特别是作为种族的功能,仍然有限。这项研究评估了这些结果,并比较了黑人和白人患者之间的差异。方法:分析退伍军人健康管理局(Veterans Health Administration)的数据,以确定在2020年12月至2023年12月期间服用relugolix的男性成年PC患者。对relugolix治疗开始后长达1年的依从性进行评估,并使用广义线性模型在种族之间进行比较。使用Kaplan-Meier分析评估relugolix停药、切换到另一种ADT和开始附加PC治疗,并使用Cox回归比较种族之间的差异。在relugolix治疗期间,PSA反应,包括从基线下降≥50%和≥90%,并达到结果:共确定507例患者(141例黑人和313例白人患者)。在治疗的前12个月,两个种族对relugolix的依从性都达到了90%,两者之间没有显著差异。在随访期间(黑人和白人患者的中位数分别为10.7和12.6个月),27.0%的黑人和21.1%的白人患者停药;9.2%的黑人和3.8%的白人患者改用另一种ADT;11.3%的黑人和10.5%的白人患者开始了附加的PC治疗。在ADT-naïve患者中,87.2%的黑人和87.2%的白人患者的PSA较基线下降≥50%;69.2%、64.1%降幅≥90%;结论:利路高利治疗第一年的依从性非常高。这些数据支持,在现实世界中,无论种族,患者都可以坚持使用relugolix,其PSA反应与临床试验相当。黑人患者比白人患者更有可能停止或改用另一种ADT,但其原因需要进一步研究。试验注册:ClinicalTrials.gov识别码,NCT06462014。
{"title":"Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration","authors":"Stephen J. Freedland,&nbsp;Krishnan Ramaswamy,&nbsp;Abhishek Kavati,&nbsp;Wei Gao,&nbsp;Juan F. Razo,&nbsp;Michele Cole,&nbsp;Benjamin Li,&nbsp;Hongbo Yang,&nbsp;Tracy Guo,&nbsp;Grace Chen,&nbsp;Rana R. McKay","doi":"10.1007/s12325-025-03390-6","DOIUrl":"10.1007/s12325-025-03390-6","url":null,"abstract":"<div><h3>Introduction</h3><p>Relugolix is the only oral androgen deprivation therapy (ADT) approved for advanced prostate cancer (PC). Real-world evidence on treatment patterns and prostate-specific antigen (PSA) responses of relugolix, especially as a function of race, remain limited. This study assessed these outcomes and compared differences between Black and White patients.</p><h3>Methods</h3><p>Veterans Health Administration data were analyzed to identify male adults with PC who initiated relugolix between December 2020 and December 2023. Adherence to relugolix was assessed for up to 1 year after treatment initiation and was compared between races using generalized linear models. Discontinuation of relugolix, switching to another ADT, and initiating an add-on PC treatment were assessed using Kaplan–Meier analyses and compared between races using Cox regressions. PSA responses during relugolix treatment, including ≥ 50% and ≥ 90% decline from baseline and achieving &lt; 0.2 ng/mL, were assessed among ADT-naïve patients.</p><h3>Results</h3><p>A total of 507 patients were identified (141 Black and 313 White patients). During the first 12 months of treatment, both races had &gt; 90% adherence to relugolix with no significant differences between them. During follow-up (median 10.7 and 12.6 months for Black and White patients, respectively), 27.0% Black and 21.1% White patients discontinued relugolix; 9.2% Black and 3.8% White patients switched to another ADT; and 11.3% Black and 10.5% White patients initiated an add-on PC treatment. Among ADT-naïve patients, 87.2% Black and 87.2% White patients achieved PSA decline ≥ 50% from baseline; 69.2% and 64.1% achieved ≥ 90% decline; 51.3% and 47.4% achieved PSA &lt; 0.2 ng/mL.</p><h3>Conclusion</h3><p>Adherence to relugolix was very high during the first year of treatment. These data support that in the real world, patients can adhere to relugolix with PSA responses on par with clinical trials regardless of race. Black patients were more likely to discontinue or switch to another ADT than White patients, but the reasons for this require further study.</p><h3>Trial registration</h3><p>ClinicalTrials.gov identifier, NCT06462014.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 12","pages":"6278 - 6294"},"PeriodicalIF":4.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03390-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145420871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion 生活与嗜酸性肉芽肿病多血管炎(EGPA):播客的医患讨论。
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-01 DOI: 10.1007/s12325-025-03400-7
Autumn Smith, Michael E. Wechsler

For people living with eosinophilic granulomatosis with polyangiitis (EGPA), the journey to diagnosis can be long and complicated. EGPA is a rare inflammatory disorder, typically characterized by high levels of blood eosinophils and vasculitis in the lungs and/or other end organ(s). It is associated with asthma, pulmonary infiltrates, neuropathy, sinus disease and the presence of anti-neutrophil cytoplasmic antibodies. Patients can present with a number of symptoms and complications, which often go unrecognized or misdiagnosed and can result in considerable delays in appropriate treatment and worsening of underlying disease. Following correct diagnosis, patients are often treated with oral corticosteroids and other immunosuppressive drugs. While these treatments can be effective at controlling disease, they are also associated with significant side effects, which can lead to diminished quality of life. The emergence in recent years of anti-interleukin-5/receptor (anti-IL-5/R) therapies, such as benralizumab and mepolizumab, has revolutionized the management of EGPA. Interleukin-5 (IL-5) is a key cytokine in the maturation, proliferation and activation of eosinophils. Anti-IL-5/R therapies work by binding IL-5 or the receptor for IL-5, thereby significantly decreasing eosinophilic inflammation, the key pathogenic driver in EPGA. Not only are anti-IL-5/R therapies effective at controlling disease, but they are also well tolerated and can facilitate corticosteroid tapering. In this podcast, a patient and physician discuss the lived experience of EGPA, including difficulties with diagnosis, impact of disease on daily life and disease management with both traditional treatments and with the newer anti-IL-5/R therapies. The discussion highlights the importance of EGPA awareness and of physicians recognizing seemingly unconnected symptoms and different disease components, as well as the need to minimize corticosteroid use because of long-term risks. Furthermore, access to an experienced and coordinated healthcare team and establishing a strong support network are emphasized as essential to help patients manage this complex and rare disease.

Podcast Audio (MP4 168118 KB)

对于患有嗜酸性肉芽肿病合并多血管炎(EGPA)的人来说,诊断的过程可能是漫长而复杂的。EGPA是一种罕见的炎症性疾病,典型特征为高水平的血嗜酸性粒细胞和肺和/或其他末端器官的血管炎。它与哮喘、肺浸润、神经病变、鼻窦疾病和抗中性粒细胞细胞质抗体的存在有关。患者可能出现许多症状和并发症,这些症状和并发症往往未被识别或误诊,并可能导致适当治疗的严重延误和基础疾病的恶化。在正确诊断后,患者通常使用口服皮质类固醇和其他免疫抑制药物治疗。虽然这些治疗方法可以有效地控制疾病,但它们也与显著的副作用相关,这可能导致生活质量下降。近年来出现的抗白细胞介素5/受体(抗il -5/R)疗法,如benralizumab和mepolizumab,已经彻底改变了EGPA的管理。白细胞介素-5 (IL-5)是嗜酸性粒细胞成熟、增殖和活化的关键细胞因子。抗IL-5/R疗法通过结合IL-5或IL-5受体起作用,从而显著降低嗜酸性粒细胞炎症,这是EPGA的关键致病驱动因素。抗il -5/R疗法不仅在控制疾病方面有效,而且耐受性良好,可以促进皮质类固醇的逐渐减少。在这期播客中,一位患者和医生讨论了EGPA的生活经历,包括诊断困难、疾病对日常生活的影响以及传统治疗和新型抗il -5/R治疗的疾病管理。讨论强调了认识EGPA的重要性,医生认识到看似不相关的症状和不同的疾病成分,以及由于长期风险而尽量减少皮质类固醇使用的必要性。此外,强调获得经验丰富和协调一致的医疗保健团队和建立强大的支持网络对于帮助患者管理这种复杂和罕见的疾病至关重要。播客音频(MP4 168118 KB)。
{"title":"Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion","authors":"Autumn Smith,&nbsp;Michael E. Wechsler","doi":"10.1007/s12325-025-03400-7","DOIUrl":"10.1007/s12325-025-03400-7","url":null,"abstract":"<div><p>For people living with eosinophilic granulomatosis with polyangiitis (EGPA), the journey to diagnosis can be long and complicated. EGPA is a rare inflammatory disorder, typically characterized by high levels of blood eosinophils and vasculitis in the lungs and/or other end organ(s). It is associated with asthma, pulmonary infiltrates, neuropathy, sinus disease and the presence of anti-neutrophil cytoplasmic antibodies. Patients can present with a number of symptoms and complications, which often go unrecognized or misdiagnosed and can result in considerable delays in appropriate treatment and worsening of underlying disease. Following correct diagnosis, patients are often treated with oral corticosteroids and other immunosuppressive drugs. While these treatments can be effective at controlling disease, they are also associated with significant side effects, which can lead to diminished quality of life. The emergence in recent years of anti-interleukin-5/receptor (anti-IL-5/R) therapies, such as benralizumab and mepolizumab, has revolutionized the management of EGPA. Interleukin-5 (IL-5) is a key cytokine in the maturation, proliferation and activation of eosinophils. Anti-IL-5/R therapies work by binding IL-5 or the receptor for IL-5, thereby significantly decreasing eosinophilic inflammation, the key pathogenic driver in EPGA. Not only are anti-IL-5/R therapies effective at controlling disease, but they are also well tolerated and can facilitate corticosteroid tapering. In this podcast, a patient and physician discuss the lived experience of EGPA, including difficulties with diagnosis, impact of disease on daily life and disease management with both traditional treatments and with the newer anti-IL-5/R therapies. The discussion highlights the importance of EGPA awareness and of physicians recognizing seemingly unconnected symptoms and different disease components, as well as the need to minimize corticosteroid use because of long-term risks. Furthermore, access to an experienced and coordinated healthcare team and establishing a strong support network are emphasized as essential to help patients manage this complex and rare disease.</p>\u0000<div><div><iframe></iframe></div><div><p>Podcast Audio (MP4 168118 KB)</p></div></div></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 12","pages":"5869 - 5878"},"PeriodicalIF":4.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03400-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes ADD2Dia:在格列齐特为基础的2型糖尿病治疗中添加钠-葡萄糖共转运蛋白2抑制剂的实际临床效果。
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-01 DOI: 10.1007/s12325-025-03394-2
Rodrigo O. Moreira, Nemencio A. Nicodemus Jr., Abdurrahman Comlekci, Miao Yu, Mussa H. Almalki

Introduction

This study investigated the real-world clinical effectiveness and tolerability of adding a sodium-glucose cotransporter 2 inhibitor (SGLT2i) to gliclazide modified release (MR)-based therapy in a sample of patients with type 2 diabetes (T2D) across five countries, and its value as an effective and well-tolerated strategy in T2D management in a diverse patient population, including those at high risk.

Methods

This non-interventional, retrospective chart review study included patients with T2D treated with gliclazide MR-based therapy and an SGLT2i for at least 60 days. The primary outcome was change in glycated hemoglobin (HbA1c) levels. Secondary outcomes included treatment patterns, proportion of patients achieving an HbA1c target < 7%, changes in lipid profile, blood pressure, weight, new-onset comorbidities, and adverse events of special interest (AESI).

Results

A total of 537 patients (47.7% female, mean age of 59.2 years, mean disease duration 10.0 years) were included, of whom 75.4% were obese/overweight and 15.1% had atherosclerotic cardiovascular disease (ASCVD). At baseline, HbA1c was uncontrolled (≥ 7%) in 87.2% of patients (mean HbA1c of 8.7% [SD 1.7]). Mean HbA1c reductions were − 1.1% (SD 1.8) at 6 months, − 0.7% (SD 1.9) at 2.4 years, and − 0.6% (SD 1.7) at 3 years. The proportion of patients with HbA1c < 7% increased from 12.8% at baseline to 29.3% at least once during follow-up. Mean body weight decreased by 1.7 kg (95% CI − 2.2, − 1.3). AESIs were reported in 40 patients (7.4%) with urinary tract infections being the most common (6.8%).

Conclusion

The first real-world study of the long-term combination of gliclazide MR and SGLT2i demonstrated its value as an effective and well-tolerated strategy in T2D management, particularly in high-risk populations. This combination provided clinically meaningful and sustained HbA1c reductions and improved cardiometabolic parameters in a diverse T2D population, with very few adverse events. These results align with current guidelines emphasizing the importance of early combination treatment and multifactorial risk management in T2D and highlight the need to address late treatment intensification indicative of clinical inertia.

Trial Registration

ClinicalTrials.gov Identifier NCT06708091.

本研究调查了在5个国家的2型糖尿病(T2D)患者样本中,在格列齐特修饰释放(MR)为基础的治疗中添加钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)的实际临床有效性和耐受性,以及其作为一种有效且耐受性良好的T2D治疗策略在不同患者群体(包括高风险患者)中的价值。方法:这项非介入性、回顾性图表回顾研究纳入了接受格列齐特磁共振治疗和SGLT2i治疗至少60天的T2D患者。主要结局是糖化血红蛋白(HbA1c)水平的变化。结果:共纳入537例患者(女性47.7%,平均年龄59.2岁,平均病程10.0年),其中75.4%为肥胖/超重,15.1%为动脉粥样硬化性心血管疾病(ASCVD)。基线时,87.2%的患者HbA1c不受控制(≥7%)(平均HbA1c为8.7% [SD 1.7])。6个月时平均HbA1c降低- 1.1% (SD 1.8), 2.4年时平均HbA1c降低- 0.7% (SD 1.9), 3年时平均HbA1c降低- 0.6% (SD 1.7)。结论:第一个关于格列齐特MR和SGLT2i长期联合应用的真实世界研究证明了它作为一种有效且耐受性良好的T2D治疗策略的价值,特别是在高危人群中。这种组合在不同的T2D人群中提供了临床意义和持续的HbA1c降低和改善的心脏代谢参数,并且很少发生不良事件。这些结果与当前的指南一致,强调了T2D早期联合治疗和多因素风险管理的重要性,并强调了解决临床惯性指示的晚期治疗强化的必要性。试验注册:ClinicalTrials.gov标识符NCT06708091。
{"title":"ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes","authors":"Rodrigo O. Moreira,&nbsp;Nemencio A. Nicodemus Jr.,&nbsp;Abdurrahman Comlekci,&nbsp;Miao Yu,&nbsp;Mussa H. Almalki","doi":"10.1007/s12325-025-03394-2","DOIUrl":"10.1007/s12325-025-03394-2","url":null,"abstract":"<div><h3>Introduction</h3><p>This study investigated the real-world clinical effectiveness and tolerability of adding a sodium-glucose cotransporter 2 inhibitor (SGLT2i) to gliclazide modified release (MR)-based therapy in a sample of patients with type 2 diabetes (T2D) across five countries, and its value as an effective and well-tolerated strategy in T2D management in a diverse patient population, including those at high risk.</p><h3>Methods</h3><p>This non-interventional, retrospective chart review study included patients with T2D treated with gliclazide MR-based therapy and an SGLT2i for at least 60 days. The primary outcome was change in glycated hemoglobin (HbA1c) levels. Secondary outcomes included treatment patterns, proportion of patients achieving an HbA1c target &lt; 7%, changes in lipid profile, blood pressure, weight, new-onset comorbidities, and adverse events of special interest (AESI).</p><h3>Results</h3><p>A total of 537 patients (47.7% female, mean age of 59.2 years, mean disease duration 10.0 years) were included, of whom 75.4% were obese/overweight and 15.1% had atherosclerotic cardiovascular disease (ASCVD). At baseline, HbA1c was uncontrolled (≥ 7%) in 87.2% of patients (mean HbA1c of 8.7% [SD 1.7]). Mean HbA1c reductions were − 1.1% (SD 1.8) at 6 months, − 0.7% (SD 1.9) at 2.4 years, and − 0.6% (SD 1.7) at 3 years. The proportion of patients with HbA1c &lt; 7% increased from 12.8% at baseline to 29.3% at least once during follow-up. Mean body weight decreased by 1.7 kg (95% CI − 2.2, − 1.3). AESIs were reported in 40 patients (7.4%) with urinary tract infections being the most common (6.8%).</p><h3>Conclusion</h3><p>The first real-world study of the long-term combination of gliclazide MR and SGLT2i demonstrated its value as an effective and well-tolerated strategy in T2D management, particularly in high-risk populations. This combination provided clinically meaningful and sustained HbA1c reductions and improved cardiometabolic parameters in a diverse T2D population, with very few adverse events. These results align with current guidelines emphasizing the importance of early combination treatment and multifactorial risk management in T2D and highlight the need to address late treatment intensification indicative of clinical inertia.</p><h3>Trial Registration</h3><p>ClinicalTrials.gov Identifier NCT06708091.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 12","pages":"6295 - 6309"},"PeriodicalIF":4.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03394-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/ Formoterol Fumarate in General Practice in England 更正:在英国普通实践中,哮喘患者开始使用糠酸氟替卡松/维兰特罗或二丙酸倍氯米松/富马酸福莫特罗的实际疗效比较研究。
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-01 DOI: 10.1007/s12325-025-03407-0
Ashley Woodcock, John Blakey, Arnaud Bourdin, Giorgio Walter Canonica, Christian Domingo, Alexander Ford, Rosie Hulme, Theo Tritton, Ines Palomares, Sanchayita Sadhu, Arunangshu Biswas, Manish Verma
{"title":"Correction to: Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/ Formoterol Fumarate in General Practice in England","authors":"Ashley Woodcock,&nbsp;John Blakey,&nbsp;Arnaud Bourdin,&nbsp;Giorgio Walter Canonica,&nbsp;Christian Domingo,&nbsp;Alexander Ford,&nbsp;Rosie Hulme,&nbsp;Theo Tritton,&nbsp;Ines Palomares,&nbsp;Sanchayita Sadhu,&nbsp;Arunangshu Biswas,&nbsp;Manish Verma","doi":"10.1007/s12325-025-03407-0","DOIUrl":"10.1007/s12325-025-03407-0","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 12","pages":"5978 - 5979"},"PeriodicalIF":4.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03407-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Perspectives on Switching Patients with Multiple Sclerosis from Anti-CD20 Therapy to Cladribine Tablets from USA-Based Advanced Practice Providers: A Podcast 从美国高级实践提供者转换多发性硬化症患者从抗cd20治疗到克拉德滨片的现实世界观点:播客。
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-01 DOI: 10.1007/s12325-025-03391-5
Christen F. Kutz, Cortnee Roman

The multiple sclerosis (MS) treatment landscape has expanded over time, becoming increasingly complex with the availability of more advanced high-efficacy therapies (HETs). In this evolving context, shared decision-making (SDM) between healthcare providers (HCPs) and patients is crucial for optimizing treatment and ensuring personalized care. Cladribine tablets (CladT), a highly effective therapy with a well-established safety profile, are approved in the USA for treating adults with relapsing MS, including those aged ≥ 50 years. Globally, more than 89,000 patients have received CladT. HCPs have considered transitioning patients from HETs, such as anti-CD20 monoclonal antibodies, to CladT. Further research is needed to understand factors influencing the decision to switch from an anti-CD20 therapy to CladT. This podcast explores real-world insights and challenges from USA-based advanced practice providers who have switched patients with MS from anti-CD20 therapies to CladT. The discussion builds on the results from a real-world retrospective survey of 100 HCPs aimed at understanding their rationale for transitioning patients from anti-CD20 therapies (e.g., ocrelizumab, ofatumumab, rituximab, ublituximab) to CladT. The survey also assessed differences in rationale for discontinuing anti-CD20 therapies and switching from anti-CD20 therapies to CladT between patients aged < 50 and ≥ 50 years. Findings revealed that the most common reasons for transitioning from anti-CD20 therapy to CladT included perception of increased efficacy on relapses (55%) and disability progression (54%), while common reasons for discontinuing anti-CD20 therapy included relapses (41%) and continued clinical activity (26%). In patients aged > 50 years, desire to avoid long-term immunosuppression (45%) was a key factor in choosing CladT after anti-CD20 therapy. Notably, AEs suggestive of immunosuppression or opportunistic infections were not reported in patients who transitioned to CladT, and no new safety signals, infections, or immunoglobulin reductions were observed. This podcast also highlights the economic benefits of CladT, the role of SDM, and recommendations based on clinical experiences.

Podcast Transcript (MP4 217843 kb)

随着时间的推移,多发性硬化症(MS)的治疗领域不断扩大,随着更先进的高效疗法(HETs)的出现,治疗变得越来越复杂。在这种不断发展的背景下,医疗保健提供者(HCPs)和患者之间的共享决策(SDM)对于优化治疗和确保个性化护理至关重要。克拉德里滨片(CladT)是一种具有良好安全性的高效疗法,已在美国被批准用于治疗成人复发性多发性硬化症,包括年龄≥50岁的患者。在全球范围内,超过89,000名患者接受了CladT治疗。HCPs已经考虑将患者从het(如抗cd20单克隆抗体)过渡到CladT。需要进一步的研究来了解影响从抗cd20治疗转向CladT治疗的因素。本播客探讨了来自美国高级实践提供者的现实世界的见解和挑战,他们将MS患者从抗cd20治疗转为CladT治疗。讨论建立在对100名HCPs的真实世界回顾性调查结果的基础上,旨在了解他们将患者从抗cd20治疗(例如,ocrelizumab, ofatumumab, rituximab, ublituximab)过渡到CladT的理由。该调查还评估了50岁患者停止抗cd20治疗和从抗cd20治疗转向CladT的理由差异,避免长期免疫抑制的愿望(45%)是抗cd20治疗后选择CladT的关键因素。值得注意的是,在过渡到CladT的患者中未报告提示免疫抑制或机会性感染的ae,也未观察到新的安全信号、感染或免疫球蛋白减少。本播客还强调了CladT的经济效益、SDM的作用以及基于临床经验的建议。播客文字记录(MP4 217843 kb)。
{"title":"Real-World Perspectives on Switching Patients with Multiple Sclerosis from Anti-CD20 Therapy to Cladribine Tablets from USA-Based Advanced Practice Providers: A Podcast","authors":"Christen F. Kutz,&nbsp;Cortnee Roman","doi":"10.1007/s12325-025-03391-5","DOIUrl":"10.1007/s12325-025-03391-5","url":null,"abstract":"<div><p>The multiple sclerosis (MS) treatment landscape has expanded over time, becoming increasingly complex with the availability of more advanced high-efficacy therapies (HETs). In this evolving context, shared decision-making (SDM) between healthcare providers (HCPs) and patients is crucial for optimizing treatment and ensuring personalized care. Cladribine tablets (CladT), a highly effective therapy with a well-established safety profile, are approved in the USA for treating adults with relapsing MS, including those aged ≥ 50 years. Globally, more than 89,000 patients have received CladT. HCPs have considered transitioning patients from HETs, such as anti-CD20 monoclonal antibodies, to CladT. Further research is needed to understand factors influencing the decision to switch from an anti-CD20 therapy to CladT. This podcast explores real-world insights and challenges from USA-based advanced practice providers who have switched patients with MS from anti-CD20 therapies to CladT. The discussion builds on the results from a real-world retrospective survey of 100 HCPs aimed at understanding their rationale for transitioning patients from anti-CD20 therapies (e.g., ocrelizumab, ofatumumab, rituximab, ublituximab) to CladT. The survey also assessed differences in rationale for discontinuing anti-CD20 therapies and switching from anti-CD20 therapies to CladT between patients aged &lt; 50 and ≥ 50 years. Findings revealed that the most common reasons for transitioning from anti-CD20 therapy to CladT included perception of increased efficacy on relapses (55%) and disability progression (54%), while common reasons for discontinuing anti-CD20 therapy included relapses (41%) and continued clinical activity (26%). In patients aged &gt; 50 years, desire to avoid long-term immunosuppression (45%) was a key factor in choosing CladT after anti-CD20 therapy. Notably, AEs suggestive of immunosuppression or opportunistic infections were not reported in patients who transitioned to CladT, and no new safety signals, infections, or immunoglobulin reductions were observed. This podcast also highlights the economic benefits of CladT, the role of SDM, and recommendations based on clinical experiences.</p>\u0000<div><div><iframe></iframe></div><div><p>Podcast Transcript (MP4 217843 kb)</p></div></div></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 12","pages":"5857 - 5868"},"PeriodicalIF":4.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03391-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Letter Regarding: “Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study” 关于“掌跖脓疱病患者的生物治疗依从性和持久性:一项真实世界的、基于索赔的研究”的回复。
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-01 DOI: 10.1007/s12325-025-03405-2
Chiara Tognaccini, Leah E. Thomas, Dina Ghanim, Steven R. Feldman, Jashin J. Wu
{"title":"Response to Letter Regarding: “Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study”","authors":"Chiara Tognaccini,&nbsp;Leah E. Thomas,&nbsp;Dina Ghanim,&nbsp;Steven R. Feldman,&nbsp;Jashin J. Wu","doi":"10.1007/s12325-025-03405-2","DOIUrl":"10.1007/s12325-025-03405-2","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 12","pages":"6313 - 6315"},"PeriodicalIF":4.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor Regarding “Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study” 致编辑关于“掌跖脓疱病患者生物治疗依从性和持久性:一项真实世界的、基于索赔的研究”的信。
IF 4 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-11-01 DOI: 10.1007/s12325-025-03404-3
Lu-Ying Wang, Yi-Hang Ding, Xiu-Juan Hou, Chen Li
{"title":"Letter to the Editor Regarding “Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study”","authors":"Lu-Ying Wang,&nbsp;Yi-Hang Ding,&nbsp;Xiu-Juan Hou,&nbsp;Chen Li","doi":"10.1007/s12325-025-03404-3","DOIUrl":"10.1007/s12325-025-03404-3","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 12","pages":"6310 - 6312"},"PeriodicalIF":4.0,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1